768 A Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Ustekinumab Maintenance Therapy in Moderate - Severe Crohn's Disease Patients: Results From IM-UNITI
William J. Sandborn(University of San Diego), Paul Rutgeerts(KU Leuven), Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Levinus A. Dieleman(University of North Carolina at Chapel Hill), Seymour Katz(New York University), Brian G. Feagan(Western University), Long-Long Gao(Janssen (United States)), Subrata Ghosh(University College Cork), Scott Lee(University of Washington), Jean–Frédéric Colombel(Icahn School of Medicine at Mount Sinai), Willem J. de Villiers(Western University), Stephan Targan, Christopher Gasink(Janssen (United States)), Jewel Johanns(Johnson & Johnson (United States)), Stephen B. Hanauer(Northwestern University)
Cited by 14
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k